Medication use as a confounding factor in the use of the cerebrospinal fluid tau/beta-amyloid42 ratio.
Wong
Victoria
V
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000069059:Atorvastatin; D015415:Biomarkers; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D011758:Pyrroles / Q000627:therapeutic use; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D016229:Amyloid beta-Peptides; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D016861:Cyclooxygenase Inhibitors; D004967:Estrogens; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010446:Peptide Fragments; D011758:Pyrroles; C075222:amyloid beta-protein (1-42); D016875:tau Proteins; D000069059:Atorvastatin